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Editorial on the Research Topic
Diet, Inflammation and Colorectal Cancer
Excess adiposity, a worldwide-growing pathological condition, is a major risk factor for colorectal
cancer (CRC) as well as an important indicator of tumor survival, prognosis and recurrence (1).
Obesity-associated low-grade chronic inflammation represents a key aspect in the connection
between diet and cancer and dietary factors, together with high body fatness, are recognized as
important determinants of CRC risk (World Cancer Research Fund/American Institute for Cancer
Research 2017—Continuous update project report: diet, nutrition, physical activity and colorectal
cancer—Available at: wcrf.org/colorectal-cancer-2017).
This Research Topic was designed to provide the reader with an overview of the impact of body
weight and adiposity, as well as of specific food compounds on the inflammatory status in health
and disease states, such as CRC. We collected original and review articles featuring the role of
specific food compounds in the regulation of immune response and their potential therapeutic
implications, the effect of polyunsaturated fatty acids (PUFA), oligosaccharides, polyphenols and
body weight in the modulation of inflammation and long-term disease outcomes, highlighting the
link between diet, inflammation, and CRC.
Adipose tissue (AT) inflammation plays a key role in obesity-associated morbidities, including
CRC. Several studies have evidenced the importance of AT dysfunction during obesity in tumor
metabolism and malignancies progression (2). However, the underlying biological processes are
complex and not yet precisely defined. With the aim to unravel the crosstalk between dysfunctional
AT in obesity and tumorigenesis, Del Cornò et al. use a RNA-sequencing approach to characterize
the transcriptomic profile of visceral adipocytes from lean and obese subjects with or without CRC.
The study reveals a complex relationship between altered visceral adiposity in obesity and cancer.
Thus, the adipocytes transcriptome was differentially affected by obesity (pathways associated with
inflammation) and CRC (TGF-β signaling and extracellular matrix remodeling), although some
common alterations were also observed. Interestingly, the body mass index (BMI) of the subjects
deeply affects the transcriptional program (cell adhesion, angiogenesis, and metabolism) of visceral
adipocytes in CRC patients. Therefore, the obesity-induced changes in visceral adipocytes may
promote colorectal tumor progression. ω3 PUFA have been shown to attenuate AT inflammation
(3), and to have beneficial effects on CRC, including risk decrease and as adjuvant therapy (4).
Here, Del Cornò et al. show that DHA, anω3 PUFA, can regulate the expression of adipocyte genes
involved in processes potentially relevant to carcinogenesis, and found a differential regulation
between ω3 and ω6 PUFA in adipocytes from lean and obese subjects.
Increased inflammasome activity in AT has been proposed as an important mediator
of obesity-induced inflammation and insulin resistance development, known mechanisms
through which obesity promotes CRC risk and progression. In their mini review, Ahechu
et al., describe the role of inflammasomes, in general and the NLRP3 inflammasome
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specifically, in carcinogenesis. In addition, they focus on
the potential of the inflammasome to form new therapeutic
strategies for the prevention and treatment of obesity-associated
CRC development.
In the last years, evidence has been achieved that specific
dietary patterns or categories of food compounds as well as
body weight are associated with increased or decreased CRC
risk. Natural products promoting human health have become
a hot topic and their potential use in the management of
neoplastic diseases has been largely explored (5). Among them,
the pectin oligosaccharides (POS) are regarded as a novel class
of functional foods with multiple health-promoting properties
including antibacterial and immune modulating activity that
can be beneficial for controlling CRC risk. In their review, Tan
et al. provide a very informative picture of the role of POS
in CRC prevention and progression emphasizing the capacity
of these compounds to modulate signaling pathways involved
in oxidative stress and inflammation. By reviewing the body
of evidence present in the literature the authors discuss the
dual role of POS in inhibiting/activating these pathways and
highlight the need of linking, either already known or novel POS
structures, with their function to improve their potential use in
clinical practice.
Dietary polyphenols are plant secondary metabolites
that have been widely studied because of their potential
protective properties in chronic/degenerative diseases including
obesity, metabolic syndrome and cancer (6, 7). In this Issue,
Mileo et al. focused in reviewing current evidence from
preclinical studies and clinical trials about the potential
beneficial role of polyphenols in CRC. The authors describe how
polyphenols modulate multiple immunomodulatory pathways,
which can contribute to counteract the inflammatory tumor
microenvironment. Moreover, there is growing evidence about
the relationships between gut microbiota composition, gut
inflammation and the risk of colon carcinogenesis (8). In this
context, the article also highlights that the cross-talk between
dietary polyphenols and gut microbiota might also account for
their immunomodulatory properties and therapeutic potential
in CRC. Finally, dietary polyphenols may not only represent
a chemopreventive treatment, but also might be helpful as
sensitizers to chemo/radiotherapies and their combination could,
therefore, minimize toxicity and side effects of conventional
oncological therapies.
In contrast to the overwhelming evidence that a higher body
fatness is associated with an increased risk of CRC, the relation
between BMI, as a measure of body fatness, and overall mortality
in CRC patients is less clear. Shahjehan et al. explore the complex
link between BMI and overall mortality in a retrospective
study among 3,799 patients from the Mayo Clinic. Within their
analyses, the authors investigate whether the association between
body fatness and overall mortality is different at different stages
of the disease. In addition, they evaluate whether a change in
someone’s body fatness is related to overall mortality in CRC
patients. Since body fatness is modifiable, it may be an important
factor to improve outcomes in CRC patients in the future.
Summarizing, this collection of articles further highlights the
importance of obesity-associated AT inflammation in creating
a more favorable situation for cancer establishment, pointing
to obesity, body weight and dietary compounds as key factors
influencing CRC risk. The articles in this topic have provided
more specific information on important mechanisms linking diet
and CRC risk. However, the underlying mechanism for diet,
obesity, and survival in CRC patients is less clear and more
research should focus on that in the future.
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